• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

PacBio and GeneDx Launches Research Collaboration

by Jasmine Pennic 08/07/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

  • PacBio, a developer of high-quality, highly accurate sequencing solutions and GeneDx, a provider in delivering improved health outcomes through genomic and clinical insights, today announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.
  • GeneDx will perform WGS sequencing and analysis of samples from 350 people including 120 enrolled in the SeqFirst WGS study at Seattle Children’s Hospital, as well as their biological parents—duos and trios—as available. 
  • Both short- and long-read WGS will be performed as researchers explore whether novel variants not previously accessible via short-read sequencing technologies may underlie certain genetic conditions.

WGS Sequencing & Analysis

SeqFirst, sponsored by GeneDx and in part funded by the Brotman Baty Institute, is a hub for genomic research and precision medicine, and collaboration among three Seattle research institutions—UW Medicine, Seattle Children’s Hospital, and Fred Hutchinson Cancer Center. GeneDx will use the PacBio Revio sequencing system to perform all long-read WGS sequencing and analysis for this study. The study intends to determine whether the increased accuracy, read length and methylation insights offered by the Revio system will enable collaborators to better explore – and potentially increase – diagnostic yield. Aggregate sequencing data including novel variants and their frequencies identified through this study will be contributed to the Consortium of Long Read Sequencing (CoLoRS) database to advance scientific understanding of variant prevalence and classification.

“For more than twenty years, we have pioneered the development of clinical diagnostics, with the goal of ending the diagnostic odyssey for patients with rare genetic diseases,” said Gustavo Stolovitzky, Ph.D., Chief Science Officer at GeneDx. “We are excited to bring together GeneDx with PacBio and the University of Washington to explore the potential of innovative methods such as long-read sequencing to improve our ability to deliver a precise genetic diagnosis for these young children.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Olive Secures $400M At A $4B Valuation to Support New Instant Claim Payment Solution

Olive Shutters Business After Sale to Waystar and Humata Health

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

FDA Grants Clearance for UltraSight's AI Cardiac Ultrasound

Israel Defense Forces to Utilize UltraSight’s PoCUS Devices in Combat

The Future of Biomarker-Based Therapy for Mental Disorder Care

The Future of Biomarker-Based Therapy for Mental Disorder Care

HLTH23: 6 Digital Health Executives Share Key Takeaways

6 Digital Health Executives Share Key Takeaways from HLTH23

HIMSS Appoints New Chief Financial Officer & General Counsel

HIMSS Appoints New Chief Financial Officer & General Counsel

GoodRx Now Offers Access to $35 Insulin to All Americans

GoodRx Now Offers Access to $35 Insulin to All Americans

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Health M&A: Financial Distress Driving Q3 Healthcare Deals

Health M&A: Financial Distress Driving Q3 Healthcare Deals

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |